Details for Patent: 7,759,308

Which drugs does patent 7,759,308 protect, and when does it expire?

Patent 7,759,308 protects SIGNIFOR LAR KIT and is included in one NDA.

This patent has forty-one patent family members in thirty-four countries.

Summary for Patent: 7,759,308

Title:	Microparticles comprising somatostatin analogues
Abstract:	Disclosed are microparticles comprising a somatostatin analogue embedded in a biocompatible pharmacologically acceptable polymer matrix for a long acting release and pharmaceutical compositions comprising such microparticles.
Inventor(s):	Ahlheim; Markus (Staufen, DE), Ausborn; Michael (Lorrach, DE), Lambert; Olivier (Spechbach-le-Haut, FR), Riemenschnitter; Marc (Freiburg, DE)
Assignee:	Novartis AG (Basel, CH)
Application Number:	10/579,186
Patent Claim Types: see list of patent claims	Compound; Composition; Device;

Understanding the Scope and Claims of United States Patent 7,759,308: A Detailed Analysis

Introduction

United States Patent 7,759,308, titled "Microparticles comprising somatostatin analogues," is a patent that delves into the development and application of microparticles containing somatostatin analogues. This patent is crucial in the field of pharmaceuticals, particularly for the treatment of conditions where somatostatin analogues are effective. Here, we will analyze the scope, claims, and the broader patent landscape surrounding this invention.

Patent Overview

Publication and Authority

The patent, US7759308B2, was issued by the United States Patent and Trademark Office (USPTO) and is currently active, although its legal status is subject to change based on various factors such as maintenance payments and potential legal challenges[4].

Inventorship and Assignees

The patent lists the inventors and assignees who are credited with the conception and reduction to practice of the invention. Correctly identifying the true and only inventors is crucial, as errors in inventorship can lead to the patent being unenforceable if deceptive intent is involved[2].

Claims and Scope

Independent Claims

The patent includes several independent claims that define the scope of the invention. These claims are critical in determining the patent's breadth and what is protected under the patent.

• Claim 1: This claim typically defines the broadest aspect of the invention, such as the composition of the microparticles comprising a somatostatin analogue embedded in a biocompatible polymer.
• Subsequent Claims: These claims narrow down the invention by specifying particular aspects, such as the size of the microparticles, the type of polymer used, and the method of administration[4].

Claim Language and Scope Metrics

The scope of a patent can be measured using metrics such as independent claim length and independent claim count. Narrower claims, as seen in this patent, are often associated with a higher probability of grant and a shorter examination process compared to broader claims[3].

Technical Details

Composition and Structure

The microparticles described in the patent contain a somatostatin analogue embedded in a biocompatible pharmacologically acceptable polymer. The polymer can be, for example, a glycolide or a similar biodegradable material. The somatostatin analogue itself can be in various forms, with specific amino acid units and configurations[4].

Size and Administration

The microparticles are designed to be of a specific size range, typically less than 5 microns, to ensure effective delivery. The patent also details the method of administration, which can be parenteral, providing a depot formulation that releases the active agent over an extended period, such as several weeks to six months[4].

Patent Landscape

Global Dossier and International Harmonization

The patent is part of a larger global patent landscape. Tools like the Global Dossier and the Common Citation Document (CCD) facilitate the integration of patent information across different IP offices, making it easier to track related applications and citations[1].

Prior Art and Citations

The patent cites prior art related to microparticles and somatostatin analogues, indicating the state of the art at the time of filing. The CCD application consolidates prior art citations from participating IP offices, helping to visualize the search results for the same invention on a single page[1].

Legal and Practical Considerations

Enforcement and Litigation

The enforceability of the patent is contingent on correct inventorship and the absence of deceptive intent. Any errors or fraudulent activities during the application process can render the patent unenforceable[2].

Small Claims Patent Court

In the context of patent litigation, there have been discussions and studies on the feasibility of a small claims patent court. This could potentially impact how disputes related to patents like US7759308B2 are handled, making the process more accessible and less costly for smaller entities[5].

Key Takeaways

• Correct Inventorship: Ensuring the correct identification of inventors is crucial for the patent's enforceability.
• Narrow Claims: The patent's claims are narrowly defined, which can facilitate a smoother examination process and stronger patent protection.
• Technical Specifics: The microparticles must be of a specific size and composition to ensure effective delivery and release of the somatostatin analogue.
• Global Integration: The patent is part of a global dossier, facilitating international harmonization and access to related patent information.
• Legal Considerations: The patent's enforceability is subject to legal scrutiny, including the potential impact of a small claims patent court.

FAQs

What is the main subject of United States Patent 7,759,308?

The main subject of this patent is the development and application of microparticles containing somatostatin analogues for pharmaceutical use.

How are the microparticles administered?

The microparticles are administered parenterally, providing a depot formulation that releases the active agent over an extended period.

What is the significance of correct inventorship in patent law?

Correct inventorship is crucial because errors or deceptive intent can render the patent unenforceable.

How does the Global Dossier impact patent searches?

The Global Dossier provides a single portal to access file histories of related applications from participating IP offices, facilitating global patent searches and harmonization.

What are the potential benefits of a small claims patent court?

A small claims patent court could make patent litigation more accessible and less costly for smaller entities, potentially streamlining the dispute resolution process.

Sources

1. USPTO: Search for patents - USPTO
2. Oregon State University: Determining Inventorship for US Patent Applications
3. SSRN: Patent Claims and Patent Scope
4. Google Patents: US7759308B2 - Microparticles comprising somatostatin analogues
5. ACUS: U.S. Patent Small Claims Court

Drugs Protected by US Patent 7,759,308

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Recordati Rare	SIGNIFOR LAR KIT	pasireotide pamoate	FOR SUSPENSION;INTRAMUSCULAR	203255-004	Jun 29, 2018		RX	Yes	No	7,759,308		Y
Recordati Rare	SIGNIFOR LAR KIT	pasireotide pamoate	FOR SUSPENSION;INTRAMUSCULAR	203255-001	Dec 15, 2014		RX	Yes	No	7,759,308		Y
Recordati Rare	SIGNIFOR LAR KIT	pasireotide pamoate	FOR SUSPENSION;INTRAMUSCULAR	203255-005	Jun 29, 2018		RX	Yes	No	7,759,308		Y
Recordati Rare	SIGNIFOR LAR KIT	pasireotide pamoate	FOR SUSPENSION;INTRAMUSCULAR	203255-002	Dec 15, 2014		RX	Yes	No	7,759,308		Y
Recordati Rare	SIGNIFOR LAR KIT	pasireotide pamoate	FOR SUSPENSION;INTRAMUSCULAR	203255-003	Dec 15, 2014		RX	Yes	Yes	7,759,308		Y

Foreign Priority and PCT Information for Patent: 7,759,308

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0326602.0	Nov 14, 2003
United Kingdom	0406241.0	Mar 19, 2004

PCT Information
PCT Filed	November 12, 2004	PCT Application Number:	PCT/EP2004/012870
PCT Publication Date:	May 26, 2005	PCT Publication Number:	WO2005/046645

International Family Members for US Patent 7,759,308

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1686964		C300716	Netherlands
European Patent Office	1686964		PA2015009	Lithuania
European Patent Office	1686964		CA 2015 00026	Denmark
European Patent Office	1686964		92701	Luxembourg
European Patent Office	1686964		197 5005-2015	Slovakia
European Patent Office	1686964		CR 2015 00026	Denmark